London
United Kingdom
65
2026-03-26
The entities that hold a legal rights for patent applications filed by inventor Thomas Simon:
Simon Thomas from London, GB has applied for patents for these inventions. The list has both pending applications and granted patents:
Signalling System
#2 | 2025-12-18CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3
#3 | 2025-11-20Cell
#4 | 2025-10-30CHIMERIC CYTOKINE RECEPTOR
#5 | 2025-09-04CHIMERIC ANTIGEN RECEPTOR
#6 | 2025-08-28BCMA/CD19 CAR FOR TREATING MULTIPLE MYELOMA
#7 | 2025-06-19CELL
#8 | 2025-01-16CHIMERIC ANTIGEN RECEPTOR
#9 | 2024-12-12CELL
#10 | 2024-09-19CELL EXPRESSING A CAR AND A TRANSCRIPTION FACTOR AND ITS USE
#11 | 2024-09-12CHIMERIC ANTIGEN RECEPTOR
#12 | 2024-03-21ENGINEERED IMMUNE CELL
#13 | 2024-03-07Cell
#14 | 2023-10-19CELL
#15 | 2023-10-19CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3
#16 | 2023-07-27Cell
#17 | 2023-05-04Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof
#18 | 2023-03-23Engineered Cytolytic Immunecell
#19 | 2023-02-23ANTI TRBC1 ANTIGEN BINDING DOMAINS
#20 | 2022-11-10CHIMERIC ANTIGEN RECEPTOR
#21 | 2022-09-15CHIMERIC CYTOKINE RECEPTOR
#22 | 2022-09-01CD79-specific chimeric antigen receptor
#23 | 2022-08-25CELL
#24 | 2022-08-18Chimeric antigen receptor
#25 | 2022-08-04ENGINEERED T-CELLS CO-EXPRESSING AN ANTI-BCMA CAR AND AN ANTI-ECTOENZYME ANTIBODY AND THEIR USE IN THE TREATMENT OF CANCER
#26 | 2022-07-07CELL
#27 | 2022-03-31Anti TRBC1 antigen binding domains
#28 | 2022-02-24CELL
#29 | 2022-02-10BINDING DOMAIN
#30 | 2022-02-03Chimeric antigen receptor
#31 | 2021-12-30Chimeric antigen receptor
#32 | 2021-11-25CELL
#33 | 2021-08-12CAR-T CELLS EXPRESSING AN INHIBITORY ANTI-TGF-BETA-RECEPTOR II SINGLE DOMAIN ANTIBODY
#34 | 2021-07-15VECTORS
#35 | 2021-04-22Chimeric antigen receptor
#36 | 2021-02-11Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors
#37 | 2021-02-11Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins
#38 | 2021-02-04ENGINEERED CYTOLYTIC IMMUNECELL
#39 | 2021-02-04POLYPEPTIDES AND METHODS
#40 | 2021-02-04CHIMERIC RECEPTOR
#41 | 2020-11-19Polypeptide
#42 | 2020-11-05CELL
#43 | 2020-10-29CELL
#44 | 2020-09-24Cell
#45 | 2020-07-30RECEPTOR
#46 | 2020-06-25CELL COMPRISING A CHIMERIC ANTIGEN RECEPTOR (CAR)
#47 | 2020-06-18A CELL COMPRISING A CHIMERIC ANTIGEN RECEPTOR (CAR)
#48 | 2020-06-11CELL
#49 | 2020-05-07Anti TRBC1 antigen binding domains
#50 | 2020-03-26TRANSCRIPTION SYSTEM
#51 | 2020-02-13Cell
#52 | 2020-01-30CELL EXPRESSING A CAR AND A TRANSCRIPTION FACTOR AND ITS USE
#53 | 2019-10-31Tunable Chimeric Antigen Receptors
#54 | 2019-10-31Signalling system
#55 | 2019-10-10SIGNAL TRANSDUCTION MODIFYING PROTEIN
#56 | 2019-06-13Chimeric antigen receptor
#57 | 2019-05-30Chimeric antigen receptor (CAR) comprising a CD19-binding domain
#58 | 2019-01-24Chimeric T cell
#59 | 2019-01-17Chimeric cytokine receptors and encoding nucleic acids
#60 | 2018-12-27Chimeric antigen receptor (CAR) comprising a CD22-binding domain
#61 | 2018-08-30Chimeric cytokine receptors and encoding nucleic acids
#62 | 2017-12-28T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor
#63 | 2017-11-30Cell
#64 | 2017-11-30Cell
#65 | 2017-03-09Chimeric antigen receptor
1817653 ⎘